InvestSMART

Clever Culture Systems Limited (ASX:CC5)

ALERT: Price-sensitive ASX Announcement for CC5
Current share price for CC5 : $0.023 0.001 (4.55%)+
Announcement
Release
30 Apr 2026 9:46AM
Price at Release
$0.022
Full Release
download
Summary
Clever Culture Systems Ltd (ASX: CC5) released its quarterly activities and Appendix 4C cash flow report for the quarter ending 31 March 2026. The company, specializing in microbiology automation using AI, highlighted significant progress in expanding its customer base, securing contracts with top global pharmaceutical companies, and maintaining a solid financial position with a cash balance of $2.0 million. During the quarter, they placed 9 APAS® Independence instruments with customers and anticipate further growth with new orders and evaluations, particularly in the pharmaceutical sector. The financial report showed net cash outflows of $1.1 million, with key expenditures on staff, R&D, and manufacturing. The company remains focused on its strategy to engage with leading pharmaceutical manufacturers and expects to secure additional top-20 customers by the end of FY26.
Key Points
  • 9 APAS® instrument placements year-to-date in FY26.
  • Expectation to meet or exceed FY25 placements of APAS® instruments.
  • Three new APAS® Independence orders in Q3 FY26.
  • Engagement with top global pharmaceutical companies including AstraZeneca, Pfizer, and Novo Nordisk.
  • Cash position of $2.0 million as of 31 March 2026.
  • Projected $2.6 million in committed cash inflows over the next two quarters.
  • Net cash outflows of $1.1 million for the quarter.
  • Continued focus on expanding the pharmaceutical customer base.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.